Preclinical evaluation of M-DGN549, a folate receptor alpha-targeting antibody–drug conjugate (ADC) with a DNA-alkylating payload
Setiady, Y, Lanieri, L, Ab, O, Maloney, E, Hong, E, Qiu, Q, Zhou, Y, Zhao, J, Themeles, M, Zhang, X, Pinkas, J, Ruiz Soto, R, Ponte, J
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens
George, S., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K.N., Somaiah, N., Trent, J.C., Rodon Ahnert, J., Wolf, J., Ruiz-Soto, R., Rosen, O., Janku, F.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
Janku, F., Bauer, S., Shoumariyeh, K., Jones, R.L., Spreafico, A., Jennings, J., Psoinos, C., Meade, J., Ruiz-Soto, R., Chi, P.
Published in ESMO open (01.08.2022)
Published in ESMO open (01.08.2022)
Get full text
Journal Article
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients
Martin, L.P, Konner, J, Moore, K.N, Seward, S.M, Matulonis, U.A, Perez, R.P, Zhou, Y, Ponte, J, Zhao, J, Ruiz-Soto, R, Birrer, M.J
Published in Gynecologic oncology (01.06.2017)
Published in Gynecologic oncology (01.06.2017)
Get full text
Journal Article
1770P Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
D'Amato, G., Wagner, A.J., Ganjoo, K.N., Stacchiotti, S., Gelderblom, H., Ryan, C.W., Palmerini, E., Ravi, V., Saleh, R., Le Cesne, A., Bernthal, N.M., van de Sande, M., Narasimhan, S., Harrow, B., Saunders, A., Ruiz-Soto, R., Sherman, M.L., Tap, W.D.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
450O Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition
Tolcher, A.W., Hong, D.S., Vandross, A., Amaravadi, R., Psoinos, C., Brennan, D., Sherman, M.L., Ruiz-Soto, R., Viswanathan, L., Sprott, K., Reu, F.J., Weekes, C.D.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
Gelderblom, H., Abdul Razak, A., Martin-Broto, J., Wilky, B.A., Rutkowski, P., Narasimhan, S., Vallee, M., Sharma, M., Ruiz-Soto, R., Sherman, M.L., Tap, W.D.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
558P A phase I study of rebastinib and carboplatin in patients with metastatic solid tumours
Janku, F., Tolcher, A.W., Rosen, L., Taglienti, C., Kuida, K., Achour, H., Ruiz-Soto, R., Munster, P.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1082P Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Janku, F., Bauer, S., Shoumariyeh, K., Jones, R.L., Spreafico, A., Jennings, J., Psoinos, C., Meade, J., Ruiz-Soto, R., Chi, P.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
LBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
Gelderblom, H., Bhadri, V.A., Stacchiotti, S., Bauer, S., Wagner, A.J., van de Sande, M., Bernthal, N.M., Lopez Pousa, A., Abdul Razak, A.R., Italiano, A., Ahmed, M., Le Cesne, A., Tait, C., Saunders, A., Harrow, B., Sharma, M.G., Ruiz-Soto, R., Sherman, M.L., Blay, J-Y., Tap, W.D.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1769P Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
Serrano, C., Blay, J-Y., Rutkowski, P., Gelderblom, H., Stacchiotti, S., Falcon Gonzalez, A., Desai, J., Le Cesne, A., Ferraresi, V., Palmerini, E., Wilky, B.A., Wagner, A.J., Bernthal, N.M., van de Sande, M., Narasimhan, S., Harrow, B., Sharma, M.G., Ruiz-Soto, R., Sherman, M.L., Tap, W.D.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
P-107 Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib
Patel, A., George, S., Janku, F., Ganjoo, K., Young, R., Chi, P., Westwood, D., Stearns, S., Meade, J., Ruiz-Soto, R., Lacouture, M.
Published in Annals of oncology (01.07.2021)
Published in Annals of oncology (01.07.2021)
Get full text
Journal Article
728P A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer
Hamilton, E.P., Goel, S., Arend, R., Chu, C., Richardson, D.L., Corr, B., John, V., Janku, F., Hays, J., Michenzie, M., Reichmann, W., Achour, H., Sherman, M.L., Ruiz-Soto, R., Mathews, C.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)
Gelderblom, H., Razak, A.R. Abdul, Sánchez-Gastaldo, A., Rutkowski, P., Wilky, B., Wagner, A., van de Sande, M., Michenzie, M., Vallee, M., Sharma, M., Sherman, M.L., Ruiz-Soto, R., Tap, W.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study
von Mehren, M., Heinrich, M.C., George, S., Zalcberg, J.R., Bauer, S., Gelderblom, H., Schöffski, P., Serrano, C., Jones, R.L., Attia, S., D'Amato, G., Chi, P., Reichardt, P., Meade, J.N., Reichert, V.L., Shi, K., Ruiz-Soto, R., Blay, J-Y.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion
Blay, J-Y., Gelderblom, H., Rutkowski, P., Wagner, A., van de Sande, M., Falcon Gonzalez, A., Stacchiotti, S., Le Cesne, A., Alcindor, T., Serrano, C., Palmerini, E., Ravi, V., Casado Herraez, A., Seddon, B., Vallee, M., Jarecha, R., Sharma, M., Ruiz-Soto, R., Sherman, M.L., Tap, W.D.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Janku, F., Chi, P., Heinrich, M., von Mehren, M., Jones, R.L., Ganjoo, K., Trent, J., Gelderblom, H., Razak, A. Abdul, Gordon, M., Somaiah, N., Jennings, J., Shi, K., Ruiz-Soto, R., George, S.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer
Hamilton, E.P., Goel, S., Arend, R., Chu, C., Richardson, D.L., Diamond, J.R., John, V., Janku, F., Matthews, C., JeBailey, L., Kuida, K., Achour, H., Ruiz-Soto, R., Hays, J.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Zalcberg, J.R., Heinrich, M., George, S., Bauer, S., Gelderblom, H., Schöffski, P., Serrano, C., Jones, R.L., Attia, S., D'Amato, G., Chi, P., Reichardt, P., Meade, J.N., Reichert, V., Shi, K., Ruiz-Soto, R., von Mehren, M., Blay, J-Y.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
P61 Health State Utility Values and Quality of Life in Patients Receiving Ripretinib in the Phase 3 Invictus Trial and a Real-World Evidence Study in China
Jones, RL, Blay, JY, Chi, P, Bauer, S, Gelderblom, H, Shen, L, He, YL, Heinrich, MC, Schöffski, P, Zalcberg, JR, Harrow, B, Sherman, ML, Ruiz-Soto, R, Becker, C, von Mehren, M
Published in Value in health (01.12.2022)
Published in Value in health (01.12.2022)
Get full text
Journal Article